OBJECTIVE: This study was undertaken to evaluate whether immunophenotyping of advanced epithelial ovarian cancer could predict response to initial chemotherapy and whether tumor immunophenotype changed after chemotherapy. STUDY DESIGN: Fifty-four patients with stage III and IV ovarian cancer, treated at the University of Washington Medical Center, had pathology specimens evaluated. A subset of 23 patients also had specimens from a secondary surgery evaluated. Using immunocytochemistry, tumors were immunostained for overexpression of c-erb-B-2, epidermal growth factor receptor (EGFR), p53, and expression of the Ki67-defined antigen (a marker of cellular proliferation), tumor necrosis factor alpha (TNFalpha), estrogen receptor (ER), progesterone receptor (PR), and P-glycoprotein (P170, a marker of multidrug resistance). Twenty-four patients had a good response to chemotherapy (defined as a negative, or microscopically positive second look), and 30 had a poor response (defined as grossly positive second look or progressive disease). RESULTS: Comparison of tumor markers from the initial and the secondary surgeries revealed that the only significant change was in the Ki67-defined cell proliferation rate, which showed a marked reduction in those with a good response to chemotherapy (P = 0.002). Comparison of tumor markers at initial surgery between good and poor responders revealed a correlation with p53 expression. Good responders were less likely to have p53 overexpression compared to poor responders, and this result approached significance (P = 0.058). Comparison of tumor markers at secondary surgery revealed a significant reduction in Ki67-defined cell proliferation rate in good responders compared to poor responders (P = 0.01). No significant differences were found between good and poor responders for the other tumor markers evaluated. CONCLUSIONS: The only tumor markers to predict for response to chemotherapy were p53 at initial surgery (P = 0.058) and Ki67 indices at secondary surgery (P = 0.001). Expression of steroid hormone receptors, TNFalpha, and P-glycoprotein and overexpression of c-erb-B-2 or EGFR are not associated with chemoresistance. Copyright 1998 Academic Press.
OBJECTIVE: This study was undertaken to evaluate whether immunophenotyping of advanced epithelial ovarian cancer could predict response to initial chemotherapy and whether tumor immunophenotype changed after chemotherapy. STUDY DESIGN: Fifty-four patients with stage III and IV ovarian cancer, treated at the University of Washington Medical Center, had pathology specimens evaluated. A subset of 23 patients also had specimens from a secondary surgery evaluated. Using immunocytochemistry, tumors were immunostained for overexpression of c-erb-B-2, epidermal growth factor receptor (EGFR), p53, and expression of the Ki67-defined antigen (a marker of cellular proliferation), tumor necrosis factor alpha (TNFalpha), estrogen receptor (ER), progesterone receptor (PR), and P-glycoprotein (P170, a marker of multidrug resistance). Twenty-four patients had a good response to chemotherapy (defined as a negative, or microscopically positive second look), and 30 had a poor response (defined as grossly positive second look or progressive disease). RESULTS: Comparison of tumor markers from the initial and the secondary surgeries revealed that the only significant change was in the Ki67-defined cell proliferation rate, which showed a marked reduction in those with a good response to chemotherapy (P = 0.002). Comparison of tumor markers at initial surgery between good and poor responders revealed a correlation with p53 expression. Good responders were less likely to have p53 overexpression compared to poor responders, and this result approached significance (P = 0.058). Comparison of tumor markers at secondary surgery revealed a significant reduction in Ki67-defined cell proliferation rate in good responders compared to poor responders (P = 0.01). No significant differences were found between good and poor responders for the other tumor markers evaluated. CONCLUSIONS: The only tumor markers to predict for response to chemotherapy were p53 at initial surgery (P = 0.058) and Ki67 indices at secondary surgery (P = 0.001). Expression of steroid hormone receptors, TNFalpha, and P-glycoprotein and overexpression of c-erb-B-2 or EGFR are not associated with chemoresistance. Copyright 1998 Academic Press.
Authors: Lillian Maggio-Price; Helle Bielefeldt-Ohmann; Piper Treuting; Brian M Iritani; Weiping Zeng; Andrea Nicks; Mark Tsang; Donna Shows; Phil Morrissey; Joanne L Viney Journal: Am J Pathol Date: 2005-06 Impact factor: 4.307
Authors: Jason A Wilken; Tayf Badri; Sarah Cross; Rhoda Raji; Alessandro D Santin; Peter Schwartz; Adam J Branscum; Andre T Baron; Adam I Sakhitab; Nita J Maihle Journal: Future Med Chem Date: 2012-03 Impact factor: 3.808
Authors: Elizabeth H Kerr; Peter J Frederick; Michael E Egger; Cecil R Stockard; Jeffery Sellers; Debbie DellaManna; Denise K Oelschlager; Hope M Amm; Isam-Eldin Eltoum; J Michael Straughn; Donald J Buchsbaum; William E Grizzle; Lacey R McNally Journal: Ann Surg Oncol Date: 2013-03-24 Impact factor: 5.344
Authors: Doris R Siwak; Mark Carey; Bryan T Hennessy; Catherine T Nguyen; Mollianne J McGahren Murray; Laura Nolden; Gordon B Mills Journal: J Oncol Date: 2009-11-19 Impact factor: 4.375
Authors: F Miyazono; R Metzger; U Warnecke-Eberz; S E Baldus; J Brabender; E Bollschweiler; W Doerfler; R P Mueller; H P Dienes; T Aikou; A H Hoelscher; P M Schneider Journal: Br J Cancer Date: 2004-08-16 Impact factor: 7.640
Authors: Michael D Oberst; Stacy Fuhrmann; Kathy Mulgrew; Maria Amann; Lily Cheng; Petra Lutterbuese; Laura Richman; Steve Coats; Patrick A Baeuerle; Scott A Hammond Journal: MAbs Date: 2014 Impact factor: 5.857